top of page
Search

Chemotherapy Agents: Mechanisms & Side Effects (MRCP Part 1)

TL;DR

For MRCP Part 1, chemotherapy questions test pattern recognition: drug class → mechanism → signature toxicity. You do not need oncology regimens; you need to identify classic adverse effects (cardiac, pulmonary, renal, neuro) and a few rescue agents. Master these associations and you will answer most exam questions quickly and safely.


Why this matters for MRCP Part 1

Cytotoxic chemotherapy is a core pharmacology topic because it integrates cell biology, adverse drug reactions, and organ-specific toxicity. MRCP questions are predictable: they ask you to link a clinical presentation (e.g. dyspnoea months later, neuropathy, haematuria) to the offending drug class, not to memorise treatment protocols. This article distils the highest-yield agents, the five most tested subtopics, and the common traps that cost marks.


Scope and exam focus

This guide covers classical cytotoxic agents (alkylators, antimetabolites, anthracyclines, platinums, microtubule inhibitors, topoisomerase inhibitors, bleomycin). Targeted therapies and immunotherapy are usually examined separately and at a lighter depth.


Medical student studying chemotherapy pharmacology for MRCP Part 1

The five most tested subtopics (what examiners love)

  1. Dose-limiting toxicities (e.g. cardiomyopathy, pulmonary fibrosis)

  2. Cell-cycle specificity (S-phase vs M-phase vs non-specific)

  3. Organ-specific damage (heart, lung, kidney, nerves)

  4. Rescue or protective agents (mesna, leucovorin)

  5. “One drug, one clue” associations (e.g. hearing loss → cisplatin)


Core chemotherapy classes: mechanisms and signature side effects

1) Alkylating agents

Examples: cyclophosphamide, ifosfamide, busulfan

  • Mechanism: DNA cross-linking → impaired replication

  • Cell cycle: Non-specific

  • Key toxicities: myelosuppression; haemorrhagic cystitis (cyclophosphamide); pulmonary fibrosis (busulfan)

  • Exam pearl: Haematuria after chemotherapy → think cyclophosphamide; prevention with mesna.

2) Antimetabolites

Examples: methotrexate, 5-fluorouracil, cytarabine

  • Mechanism: inhibit nucleotide synthesis

  • Cell cycle: S-phase specific

  • Key toxicities: myelosuppression, mucositis; hepatotoxicity (methotrexate)

  • Exam pearl: Methotrexate toxicity is rescued with leucovorin (folinic acid).

3) Anthracyclines

Examples: doxorubicin, daunorubicin

  • Mechanism: topoisomerase II inhibition + free radical formation

  • Key toxicity: dose-dependent cardiomyopathy

  • Exam pearl: Delayed dilated cardiomyopathy months to years later → anthracycline exposure.

4) Platinum compounds

Examples: cisplatin, carboplatin

  • Mechanism: DNA cross-linking

  • Key toxicities: nephrotoxicity, ototoxicity, peripheral neuropathy

  • Exam pearl: Renal impairment plus hearing loss → cisplatin.

5) Microtubule inhibitors – vinca alkaloids

Examples: vincristine, vinblastine

  • Mechanism: inhibit microtubule polymerisation

  • Cell cycle: M-phase

  • Key toxicity: peripheral neuropathy (vincristine)

6) Microtubule inhibitors – taxanes

Examples: paclitaxel, docetaxel

  • Mechanism: stabilise microtubules (prevent depolymerisation)

  • Key toxicities: peripheral neuropathy, myelosuppression

7) Topoisomerase inhibitors

Examples: irinotecan (Topo I), etoposide (Topo II)

  • Key toxicity: severe diarrhoea (irinotecan)

8) Bleomycin

  • Mechanism: free radical-mediated DNA damage

  • Key toxicity: pulmonary fibrosis

  • Exam pearl: Causes lung toxicity with minimal myelosuppression.


One-look exam table (high yield)

Drug / Class

Mechanism

Signature toxicity

Cyclophosphamide

DNA alkylation

Haemorrhagic cystitis

Methotrexate

DHFR inhibition

Mucositis, hepatotoxicity

Doxorubicin

Topo II inhibition

Cardiomyopathy

Cisplatin

DNA cross-links

Nephrotoxicity, ototoxicity

Vincristine

↓ Microtubules

Peripheral neuropathy

Bleomycin

Free radicals

Pulmonary fibrosis

Practical mini-case (exam style)

Question: A 54-year-old man previously treated for lymphoma presents with progressive exertional dyspnoea eight months after completing chemotherapy. Echocardiography shows dilated cardiomyopathy. Which drug is the most likely cause?

Answer: Doxorubicin.

Explanation: Anthracyclines cause dose-related cardiomyopathy via free radical injury. The delayed onset is characteristic and frequently tested.


Five common MRCP traps (avoid these)

  • Confusing vincristine neuropathy with vinblastine (more marrow suppression)

  • Forgetting that bleomycin spares bone marrow

  • Missing leucovorin rescue in methotrexate toxicity questions

  • Mixing up cisplatin nephrotoxicity with carboplatin (less renal toxicity)

  • Assuming all chemotherapy is cell-cycle specific (alkylators are not)


Practical study-tip checklist

Use this before sitting the exam:

  • ☐ Can I name one unique toxicity for each major class?

  • ☐ Do I know which agents damage heart, lung, kidney, or nerves?

  • ☐ Can I identify rescue/protective agents (mesna, leucovorin)?

  • ☐ Have I practised pattern-based MCQs, not rote lists?

  • ☐ Have I linked chemotherapy with haematological malignancies?


FAQs

Which chemotherapy toxicities are most tested in MRCP Part 1?

Cardiotoxicity (anthracyclines), pulmonary fibrosis (bleomycin), nephrotoxicity and ototoxicity (cisplatin), and peripheral neuropathy (vinca alkaloids).

Do I need to memorise chemotherapy regimens for MRCP?

No. The exam tests mechanisms and adverse effects, not clinical oncology protocols.

How can I quickly identify the offending chemotherapy drug in questions?Look for the organ system affected and match it to a classic toxicity rather than the cancer type.

Is chemotherapy still a core topic despite newer cancer therapies?

Yes. Classical cytotoxics remain high-yield and repeatedly examined.


Ready to start?

Consolidate this topic with timed questions from the MRCP question bank and test retention using a mock exam. For structured revision, link this article with the anticancer pharmacology hub.


Sources

 
 
 

Comments

bottom of page